Determining Influenza Vaccine Effectiveness (DIVE)

确定流感疫苗的有效性 (DIVE)

• 批准号: 9353955
• 负责人: HELEN Keipp TALBOT
• 金额: $ 55.24万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9353955
• 关键词: Determining; Influenza; Vaccine; Effectiveness; DIVE

 DESCRIPTION (provided by applicant): Influenza remains an important cause of morbidity and mortality worldwide. In the United States alone, seasonal (inter pandemic) influenza is responsible for more than 200,000 hospitalizations and more than 23,000 deaths per year. The primary strategy to attenuate the impact of influenza epidemics is vaccination. Currently, the Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for all persons aged 6 months or older. However, some of these recommendations have been questioned, and the paucity of vaccine effectiveness estimates based on laboratory confirmed influenza disease further fuels this controversy. Furthermore, because influenza viruses and vaccines change annually, and because recommendations for these vaccines now cover most of the US population, annual assessments of vaccine effectiveness are needed to assess whether influenza vaccination is having its intended effects. Vanderbilt investigators have conducted prospective population- based surveillance for laboratory confirmed influenza for both the NIH and the CDC. We propose to conduct prospective surveillance in Davidson County, TN, with the following specific aims: 1) To conduct active population-based surveillance in adults hospitalized for laboratory confirmed influenza, to determine age-specific rates of influenza-associated hospitalizations; and, 2) To determine influenza vaccine effectiveness annually, using a case-control study design, among influenza positive adults hospitalized for influenza and influenza negative hospitalized controls. Vanderbilt investigators are experienced in conducting active prospective population-based hospital surveillance of laboratory confirmed influenza infections and in assessments of the effectiveness of influenza vaccines.

 描述（由适用提供）：流感仍然是全球发病率和死亡率的重要原因。仅在美国，季节性（间流行）影响力就会导致超过20万个住院和每年23,000多人死亡。衰减流行流行影响的主要策略是疫苗接种。目前，免疫实践咨询委员会（ACIP）建议所有6个月以上的人年度流感疫苗。但是，其中一些建议受到质疑，并且基于实验室的疫苗有效性估计很少，证实了影响力疾病进一步促进了这一争议。此外，由于影响病毒和疫苗每年都会发生变化，并且由于这些疫苗的建议现在涵盖了美国大多数人群，因此需要对疫苗有效性的年度评估来评估流感疫苗是否具有其预期影响。范德比尔特研究人员已经对实验室进行了前瞻性基于人群的监视，确认了NIH和CDC的影响力。我们建议在田纳西州戴维森县进行前瞻性监视，其特定目的：1）在住院的实验室确认影响力的成年人中进行积极的基于人群的监视，以确定影响与患者相关的患病率特定年龄的率； 2）在有影响力的疫苗阳性成年人中，每年使用病例对照研究设计确定影响者疫苗的有效性，用于影响者和有影响力的疫苗疫苗负阴性住院对照。范德比尔特的研究人员经验丰富，对实验室确认的有影响力者和评估有影响力疫苗的有效性进行了积极的前瞻性医院监测。